

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)



(10) International Publication Number
WO 2024/239001 A2


- (51) **International Patent Classification:**
C07D 405/02 (2006.01) *A61K 31/4025* (2006.01)
- (21) **International Application Number:**
PCT/US2024/030111
- (22) **International Filing Date:**
17 May 2024 (17.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/503,156 18 May 2023 (18.05.2023) US
- (71) **Applicant: ENVEDA THERAPEUTICS, INC.** [US/US];
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).
- (72) **Inventors: GOTTUMUKKALA, Subbaraju Venkata;** c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, AP 530003 Visakhapatnam (US). **CHERUKUPALLI, Kiran;** c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, AP 530003 Visakhapatnam (US). **NORMAN, Bryan Hurst;** c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US).

JADHAV, Prabhakar K; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **KARATHANASIS, Sotirios K;** c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **MANDAL, Goutam;** c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **MUKHOPADHYAY, Indranil;** c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, Visakhapatnam AP 530003 (IN).

(74) **Agent: CHOI, Anita et al.;** Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) **Title:** ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME



(57) **Abstract:** The present disclosure relates generally to compounds, compositions, and methods for treating a variety of diseases and conditions using a therapeutically effective amount of a compound of Formula (I) or Formula (II), a pharmaceutically acceptable salt, or derivative thereof.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*